<table border="1" cellpadding="0" cellspacing="0" width="75%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2: Clinically Significant Drug Interactions with Opana</caption>
<col width="90.9pt"></col>
<col width="369.9pt"></col>
<tbody>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="bold">Alcohol</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>The concomitant use of alcohol with OPANA can result in an increase of oxymorphone plasma levels and potentially fatal overdose of oxymorphone.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products containing alcohol while on OPANA therapy [see <content stylecode="italics">Clinical Pharmacology (<linkhtml href="#LINK_2bc018a6-7395-4216-880e-0ac561ae79d4">12.3</linkhtml>)</content>].</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Due to additive pharmacologic effect, the concomitant use of benzodiazepines and other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[</content>
<content stylecode="italics">Warnings and Precautions (<linkhtml href="#LINK_6a9d3791-e130-4baf-96b5-d03002092a24">5.4</linkhtml>)]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Benzodiazepines and other sedatives/hypnotics, anxiolytics tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Serotonergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue OPANA if serotonin syndrome is suspected.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#LINK_69a62aff-d65d-4c12-955e-233f1f6bd825">5.2</linkhtml>)].</content>
</paragraph>
<paragraph>If urgent use of an opioid is necessary, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>The use of OPANA is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>phenelzine, tranylcypromine, linezolid</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>May reduce the analgesic effect of OPANA and/or precipitate withdrawal symptoms.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Avoid concomitant use.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>butorphanol, nalbuphine, pentazocine, buprenorphine,</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Muscle Relaxants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Oxymorphone may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of OPANA and/or the muscle relaxant as necessary.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Diuretics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor patients for signs of urinary retention or reduced gastric motility when OPANA is used concomitantly with anticholinergic drugs.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Anticholinergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor patients for signs of urinary retention or reduced gastric motility when OPANA is used concomitantly with anticholinergic drugs.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Cimetidine</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Cimetidine can potentiate opioid-induced respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor patients for respiratory depression when OPANA and cimetidine are used concurrently.</paragraph>
</td>
</tr>
</tbody>
</table>